imbruvica®
By Your Side
Patient Support

Your Guide to Your IMBRUVICA® (ibrutinib) Treatment Plan

Personalized support for people living with CLL/SLL

What is IMBRUVICA® (ibrutinib)?

IMBRUVICA® (ibrutinib) is a prescription medicine used to treat:

- Adults with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL).
- Adults with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion.

It is not known if IMBRUVICA® is safe and effective in children.

SELECT IMPORTANT SIDE EFFECT INFORMATION

IMBRUVICA® may cause serious side effects, including bleeding problems (hemorrhage); infections; heart rhythm problems (ventricular arrhythmias, atrial fibrillation, and atrial flutter); heart failure and death; high blood pressure (hypertension); decrease in blood cell counts; second primary cancers; and tumor lysis syndrome (TLS).

Please see additional Important Side Effect Information on pages 15-18.

Please see the accompanying full Important Product Information at www.imbruvica.com/prescribing-information.

imbruvica®
(ibrutinib)
420, 280, 140 mg tablets | 140, 70 mg capsules

Table of Contents

SELECT IMPORTANT SIDE EFFECT INFORMATION (cont'd)

IMBRUVICA® may cause serious side effects, including: Bleeding problems (hemorrhage) are common during treatment with IMBRUVICA®, and can also be serious and may lead to death. Your risk of bleeding may increase if you are also taking a blood thinner medicine. Tell your healthcare provider if you have any signs of bleeding, including: blood in your stools or black stools (looks like tar), pink or brown urine, unexpected bleeding, or bleeding that is severe or that you cannot control, vomit blood or vomit looks like coffee grounds, cough up blood or blood clots, increased bruising, dizziness, weakness, confusion, change in your speech, or a headache that lasts a long time or severe headache.

Please see additional Important Side Effect Information on pages 15-18.

Please see the accompanying full Important Product Information at www.imbruvica.com/prescribing-information.

imbruvica® By Your Side Patient Support

imbruvica® (ibrutinib)
420, 280, 140 mg tablets | 140, 70 mg capsules

Dedicated Support to Help You Stay on Track

We're here to help

It's normal to have questions as you start your treatment with IMBRUVICA®.

This brochure has been designed to answer your questions. It can help you better understand CLL/SLL and how IMBRUVICA® works, as well as provide you with useful tips to help you during your treatment.

IMBRUVICA® By Your Side* patient support has more helpful resources created just for you. They can give you the support you need, when you need it.

Questions?

Call your IMBRUVICA® **By Your Side Ambassador†** Monday-Friday, 8AM-8PM ET at **1-888-YourSide (1-888-968-7743)** or visit **IMBRUVICAByYourSide.com**.

*IMBRUVICA® By Your Side patient support program is not intended to provide medical advice, replace prescribed treatment plans, or provide treatment or case management services. Patients are advised to talk to their healthcare provider and treatment team about any medical decisions and concerns they may have.

†By Your Side Ambassadors are provided by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie Company, and do not work under the direction of your healthcare professional (HCP) or give medical advice. They are trained to direct patients to their HCP for treatment-related advice, including further referrals.

Please see Important Side Effect Information on pages 15-18.
Please see the accompanying full Important Product Information at www.imbruvica.com/prescribing-information.

imbruvica® By Your Side Patient Support

imbruvica® (ibrutinib)
420, 280, 140 mg tablets | 140, 70 mg capsules

Understanding CLL/SLL

What are chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)?[1,2]



In CLL/SLL, cancer occurs in **B cells, a type of white blood cell**. B cells are an important part of your immune system, which defends your body against infection.

In CLL/SLL, **abnormal B cells grow and spread in the bloodstream, bone marrow, and lymphoid tissue**. They can also crowd out healthy cells in several parts of the body, causing CLL/SLL symptoms.

What is the difference between CLL and SLL?[1,2]

The main difference is where the cancer cells are found.



In CLL, most of the cancer cells are in the **blood and bone marrow**, where most blood cells are made.

In SLL, the cancer cells are mainly in the **lymph nodes**. These are glands that contain immune cells that fight infection.

If you need some help understanding CLL/SLL, call your Ambassador at **1-888-YourSide (1-888-968-7743)**.

Please see Important Side Effect Information on pages 15-18.
Please see the accompanying full Important Product Information at www.imbruvica.com/prescribing-information.

imbruvica® By Your Side Patient Support

imbruvica® (ibrutinib)
420, 280, 140 mg tablets | 140, 70 mg capsules

How IMBRUVICA® (ibrutinib) Works[3]

IMBRUVICA® is not chemotherapy. It works differently.

B cells need a protein called Bruton's tyrosine kinase (BTK) to survive.



BTK sends "signals" that help B cells stay alive and multiply. In CLL or SLL, some of these B cells are cancerous.



IMBRUVICA® binds to BTK, which in turn **blocks these signals**. This helps stop B cells including cancerous B cells from surviving and slows the spread of CLL or SLL.



Because BTK is found in normal B cells, blocking it may cause side effects. A relationship between how IMBRUVICA® works and why it helps to treat CLL or SLL has not been clearly identified.

SELECT IMPORTANT SIDE EFFECT INFORMATION (cont'd)

IMBRUVICA® may cause serious side effects, including: Infections can happen during treatment with IMBRUVICA®. These infections can be serious and may lead to death. Tell your healthcare provider right away if you have fever, chills, weakness, confusion, or other signs or symptoms of an infection during treatment with IMBRUVICA®.

Please see additional Important Side Effect Information on pages 15-18.

Please see the accompanying full Important Product Information at www.imbruvica.com/prescribing-information.

imbruvica® By Your Side Patient Support

imbruvica® (ibrutinib)
420, 280, 140 mg tablets | 140, 70 mg capsules

IMBRUVICA® (ibrutinib) Has Helped Many People With CLL/SLL Live Longer[3]

56% lower risk of death compared to those taking a chemotherapy (chlorambucil)[3]

In one clinical trial of 269 people aged 65 and older with CLL or SLL who had not been treated before, people who took IMBRUVICA® had a 56% lower risk of death compared to those taking a chemotherapy (chlorambucil). With a median follow-up of approximately 28 months, 8% of IMBRUVICA® patients died compared to 16% taking a chemotherapy.[3]

57% lower risk of death compared to those taking an immunotherapy (ofatumumab)[3]

In another clinical trial of 391 previously treated people with CLL or SLL, people who took IMBRUVICA® had a 57% lower risk of death compared to those taking an immunotherapy (ofatumumab). With a median follow-up of approximately 9 months, 8% of IMBRUVICA® patients died compared to 17% taking an immunotherapy.[3]

SELECT IMPORTANT SIDE EFFECT INFORMATION (cont'd)

IMBRUVICA® may cause serious side effects, including: Heart problems. Serious heart rhythm problems (ventricular arrhythmias, atrial fibrillation and atrial flutter), heart failure and death have happened in people treated with IMBRUVICA®, especially in people who have an infection, an increased risk for heart disease, or have had heart rhythm problems in the past. Your heart function will be checked before and during treatment with IMBRUVICA®. Tell your healthcare provider if you get any symptoms of heart problems, such as feeling as if your heart is beating fast and irregular, lightheadedness, dizziness, shortness of breath, swelling of the feet, ankles or legs, chest discomfort, or you faint. If you develop any of these symptoms, your healthcare provider may do tests to check your heart and may change your IMBRUVICA® dose.

Please see additional Important Side Effect Information on pages 15-18.

Please see the accompanying full Important Product Information at www.imbruvica.com/prescribing-information.

imbruvica® By Your Side Patient Support

imbruvica® (ibrutinib)
420, 280, 140 mg tablets | 140, 70 mg capsules

IMBRUVICA® lowered the risk of disease progression or death vs approved therapies[3]

84% lower risk of disease progression or death compared to those taking a chemotherapy (chlorambucil)[3,4]

In one clinical trial of 269 people aged 65 and older with CLL or SLL who had not been treated before, people who took IMBRUVICA® had an 84% lower risk of disease progression or death compared to those taking a chemotherapy. With a median follow-up of 18 months, 11% of IMBRUVICA® patients had disease progression or died compared to 48% taking a chemotherapy.[3,5]

78% lower risk of disease progression or death compared to those taking an immunotherapy (ofatumumab)[3]

In another clinical trial of 391 previously treated people with CLL or SLL, people who took IMBRUVICA® had a 78% lower risk of disease progression or death compared to those taking an immunotherapy. With a median follow-up of approximately 9 months, 18% of IMBRUVICA® patients had disease progression or died compared to 57% taking an immunotherapy.[3]

IMBRUVICA® will not work for every patient. Individual results may vary.

#1 Based on IQVIA data as of the most recent 3 months.

IMBRUVICA® is the #1 prescribed therapy for total CLL/SLL patients[5]

SELECT IMPORTANT SIDE EFFECT INFORMATION (cont'd)

IMBRUVICA® may cause serious side effects, including: High blood pressure (hypertension). New or worsening high blood pressure has happened in people treated with IMBRUVICA®. Your healthcare provider may start you on blood pressure medicine or change current medicines to treat your blood pressure.

Please see additional Important Side Effect Information on pages 15-18.

Please see the accompanying full Important Product Information at www.imbruvica.com/prescribing-information.

imbruvica® By Your Side Patient Support

imbruvica® (ibrutinib)
420, 280, 140 mg tablets | 140, 70 mg capsules

Possible Side Effects of IMBRUVICA® (ibrutinib)[3]

IMBRUVICA® may cause serious side effects, including:

- Bleeding problems (hemorrhage)
- Infections
- Heart rhythm problems (ventricular arrhythmias, atrial fibrillation, and atrial flutter); heart failure and death
- High blood pressure (hypertension)
- Decrease in blood cell counts
- Second primary cancers
- Tumor lysis syndrome (TLS)*

*TLS is a disorder caused by the breakdown products of cancer cells, which can lead to kidney failure and other abnormalities.

SELECT IMPORTANT SIDE EFFECT INFORMATION (cont'd)

IMBRUVICA® may cause serious side effects, including: Decrease in blood cell counts. Decreased blood counts (white blood cells, platelets, and red blood cells) are common with IMBRUVICA®, but can also be severe. Your healthcare provider should do monthly blood tests to check your blood counts.

Please see additional Important Side Effect Information on pages 15-18.

Please see the accompanying full Important Product Information at www.imbruvica.com/prescribing-information.

imbruvica® By Your Side Patient Support

imbruvica® (ibrutinib)
420, 280, 140 mg tablets | 140, 70 mg capsules

The most common (≥30%) adverse reactions in patients with CLL/SLL receiving IMBRUVICA® were[3]:

- Decrease in platelet count
- Diarrhea
- Tiredness
- Muscle and bone pain
- Decrease in white blood cell count
- Rash
- Decrease in red blood cell count
- Bruising
- Nausea

This is not a complete list of side effects. Others may occur. Tell your doctor if you think you are experiencing side effects.

In the clinical trials, approximately 4% to 10% of CLL or SLL patients stopped taking IMBRUVICA® because of side effects.

If you need help preparing to discuss side effects with your doctor, call your Ambassador at **1-888-YourSide (1-888-968-7743)** or visit **IMBRUVICAByYourSide.com**.

SELECT IMPORTANT SIDE EFFECT INFORMATION (cont'd)

IMBRUVICA® may cause serious side effects, including: Second primary cancers. New cancers have happened during treatment with IMBRUVICA®, including cancers of the skin or other organs.

Please see additional Important Side Effect Information on pages 15-18.

Please see the accompanying full Important Product Information at www.imbruvica.com/prescribing-information.

imbruvica® By Your Side Patient Support

imbruvica® (ibrutinib)
420, 280, 140 mg tablets | 140, 70 mg capsules

Fit IMBRUVICA® (ibrutinib) Into Your Daily Routine

The once-daily oral therapy you can take anywhere[3]

IMBRUVICA® is a medicine you take once a day, at about the same time each day, exactly as prescribed by your doctor.[3]

To help you stick to your treatment plan, it's recommended you build a routine for taking IMBRUVICA®. It will make your medicine a natural part of your day—every day.

How should I take IMBRUVICA®[3]:

- Take IMBRUVICA® exactly as your healthcare provider tells you to take it.
- Take IMBRUVICA® 1 time a day at about the same time each day.

IMBRUVICA® comes as capsules or tablets.

- If your healthcare provider prescribes IMBRUVICA® capsules or tablets:
  - Swallow IMBRUVICA® capsules or tablets whole with a glass of water.
  - Do not open, break, or chew IMBRUVICA® capsules.
  - Do not cut, crush, or chew IMBRUVICA® tablets.
- If you miss a dose of IMBRUVICA® take it as soon as you remember on the same day. Take your next dose of IMBRUVICA® at your regular time on the next day. Do not take extra doses of IMBRUVICA® to make up for a missed dose.
- If you take too much IMBRUVICA® call your healthcare provider or go to the nearest hospital emergency room right away.

Please see Important Side Effect Information on pages 15-18.

Please see the accompanying full Important Product Information at www.imbruvica.com/prescribing-information.

imbruvica® By Your Side Patient Support

imbruvica® (ibrutinib)
420, 280, 140 mg tablets | 140, 70 mg capsules

Try taking IMBRUVICA® at the same time you do a daily activity, like:

- Before/after walking your dog
- After you eat breakfast or lunch
- Reading the newspaper

What should I avoid while taking IMBRUVICA®?[3]

You should not drink grapefruit juice, eat grapefruit, or eat Seville oranges (often used in marmalades) during treatment with IMBRUVICA®. These products may increase the amount of IMBRUVICA® in your blood.

SELECT IMPORTANT SIDE EFFECT INFORMATION (cont'd)

IMBRUVICA® may cause serious side effects, including: Tumor lysis syndrome (TLS). TLS is caused by the fast breakdown of cancer cells. TLS can cause kidney failure and the need for dialysis treatment, abnormal heart rhythm, seizure, and sometimes death. Your healthcare provider may do blood tests to check you for TLS.

Please see additional Important Side Effect Information on pages 15-18.

Please see the accompanying full Important Product Information at www.imbruvica.com/prescribing-information.

imbruvica® By Your Side Patient Support

imbruvica® (ibrutinib)
420, 280, 140 mg tablets | 140, 70 mg capsules

One-on-one Support to Help You Throughout Your Treatment

With **IMBRUVICA® By Your Side*** patient support, you get your own dedicated **IMBRUVICA® By Your Side Ambassador** committed to listening to you and helping you along the way. Every time you call, you will speak to the same person. They will:

- Provide personalized support and resources to help you stay on track with your treatment plan
- Connect you with an Insurance Specialist to help answer questions about cost and coverage
- Answer questions you may have about IMBRUVICA® and your disease

Call your **IMBRUVICA® By Your Side Ambassador** with any questions about IMBRUVICA® at **1-888-YourSide (1-888-968-7743)**.

*IMBRUVICA® By Your Side patient support program is not intended to provide medical advice, replace prescribed treatment plans, or provide treatment or case management services. Patients are advised to talk to their healthcare provider and treatment team about any medical decisions and concerns they may have.

Please see Important Side Effect Information on pages 15-18.
Please see the accompanying full Important Product Information at www.imbruvica.com/prescribing-information.

imbruvica® By Your Side Patient Support

imbruvica® (ibrutinib)
420, 280, 140 mg tablets | 140, 70 mg capsules

Financial Assistance for You

By Your Side patient support is here to help you understand your options for affording IMBRUVICA®.

Insurance Specialists

- Guide you through the insurance process, including pre-authorization
- Identify potential savings on the cost of your prescription

Treatment Cost Resources

- Affordability and support resources for patients
- Commercially insured patients may pay as little as $0 per prescription*

If you have questions about cost and coverage, call an Insurance Specialist at **1-888-YourSide (1-888-968-7743)**.

*Eligibility: Available to patients with commercial insurance coverage for IMBRUVICA® (ibrutinib) who meet eligibility criteria. This copay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. **For full Terms and Conditions, visit https://www.imbruvica.com/imbruvica-by-your-side or call 1-888-968-7743 for additional information.** For information on how we collect and process your personal data, including the categories we collect, purposes for their collection, and disclosures to third parties, visit https://www.pharmacyclics.com/privacy-notice.html#info_pcp.

Please see Important Side Effect Information on pages 15-18.

Please see the accompanying full Important Product Information at www.imbruvica.com/prescribing-information.

imbruvica® By Your Side Patient Support

imbruvica® (ibrutinib)
420, 280, 140 mg tablets | 140, 70 mg capsules

Support and Resources

Below are some resources that both patients and caregivers may find helpful as patients begin their treatment:

CancerCare® **www.cancercare.org**

Cancer Support Community **www.cancersupportcommunity.org**

CLL Society **www.cllsociety.org**

Leukemia & Lymphoma Society **www.lls.org**

Lymphoma Research Foundation **www.lymphoma.org**

National Alliance for Caregiving **www.caregiving.org**

Please see Important Side Effect Information on pages 15-18.
Please see the accompanying full Important Product Information at www.imbruvica.com/prescribing-information.

imbruvica® By Your Side Patient Support

imbruvica® (ibrutinib)
420, 280, 140 mg tablets | 140, 70 mg capsules

IMPORTANT SIDE EFFECT INFORMATION

Before taking IMBRUVICA®, tell your healthcare provider about all of your medical conditions, including if you:

- have had recent surgery or plan to have surgery. Your healthcare provider may stop IMBRUVICA® for any planned medical, surgical, or dental procedure.
- have bleeding problems
- have or had heart rhythm problems, smoke, or have a medical condition that increases your risk of heart disease, such as high blood pressure, high cholesterol, or diabetes
- have an infection
- have liver problems
- are pregnant or plan to become pregnant. IMBRUVICA® can harm your unborn baby. If you are able to become pregnant, your healthcare provider will do a pregnancy test before starting treatment with IMBRUVICA®. Tell your healthcare provider if you are pregnant or think you may be pregnant during treatment with IMBRUVICA®.
    - **Females** who are able to become pregnant should use effective birth control (contraception) during treatment with IMBRUVICA® and for 1 month after the last dose.
    - **Males** with female partners who are able to become pregnant should use effective birth control, such as condoms, during treatment with IMBRUVICA® and for 1 month after the last dose.
- are breastfeeding or plan to breastfeed. Do not breastfeed during treatment with IMBRUVICA® and for 1 week after the last dose.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking IMBRUVICA® with certain other medicines may affect how IMBRUVICA® works and can cause side effects.

How should I take IMBRUVICA®?

- Take IMBRUVICA® exactly as your healthcare provider tells you to take it.
- Take IMBRUVICA® 1 time a day at about the same time each day.

IMBRUVICA® comes as capsules or tablets.

- **If your healthcare provider prescribes IMBRUVICA® capsules or tablets:**
    - Swallow IMBRUVICA® capsules or tablets whole with a glass of water.
    - Do not open, break, or chew IMBRUVICA® capsules.
    - Do not cut, crush, or chew IMBRUVICA® tablets.

Important Side Effect Information continued on next page.

Please see the accompanying full Important Product Information at www.imbruvica.com/prescribing-information.

imbruvica®
(ibrutinib)
420, 280, 140 mg tablets | 140, 70 mg capsules

IMPORTANT SIDE EFFECT INFORMATION (cont'd)

- If you miss a dose of IMBRUVICA® take it as soon as you remember on the same day. Take your next dose of IMBRUVICA® at your regular time on the next day. Do not take extra doses of IMBRUVICA® to make up for a missed dose.
- If you take too much IMBRUVICA® call your healthcare provider or go to the nearest hospital emergency room right away.

What should I avoid while taking IMBRUVICA®?

- You should not drink grapefruit juice, eat grapefruit, or eat Seville oranges (often used in marmalades) during treatment with IMBRUVICA®. These products may increase the amount of IMBRUVICA® in your blood.

What are the possible side effects of IMBRUVICA®?

IMBRUVICA® may cause serious side effects, including:

- **Bleeding problems (hemorrhage) are common** during treatment with IMBRUVICA®, and can also be serious and may lead to death. Your risk of bleeding may increase if you are also taking a blood thinner medicine. Tell your healthcare provider if you have any signs of bleeding, including: blood in your stools or black stools (looks like tar), pink or brown urine, unexpected bleeding, or bleeding that is severe or that you cannot control, vomit blood or vomit looks like coffee grounds, cough up blood or blood clots, increased bruising, dizziness, weakness, confusion, change in your speech, or a headache that lasts a long time or severe headache.
- **Infections** can happen during treatment with IMBRUVICA®. These infections can be serious and may lead to death. Tell your healthcare provider right away if you have fever, chills, weakness, confusion, or other signs or symptoms of an infection during treatment with IMBRUVICA®.
- **Heart problems.** Serious heart rhythm problems (ventricular arrhythmias, atrial fibrillation and atrial flutter), heart failure and death have happened in people treated with IMBRUVICA®, especially in people who have an infection, an increased risk for heart disease, or have had heart rhythm problems in the past. Your heart function will be checked before and during treatment with IMBRUVICA®. Tell your healthcare provider if you get any symptoms of heart problems, such as feeling as if your heart is beating fast and irregular, lightheadedness, dizziness, shortness of breath, swelling of the feet, ankles or legs, chest discomfort, or you faint. If you develop any of these symptoms, your healthcare provider may do tests to check your heart and may change your IMBRUVICA® dose.

Important Side Effect Information continued on next page.

Please see the accompanying full Important Product Information at www.imbruvica.com/prescribing-information.

imbruvica®
(ibrutinib)
420, 280, 140 mg tablets | 140, 70 mg capsules

IMPORTANT SIDE EFFECT INFORMATION (cont'd)

- **High blood pressure (hypertension).** New or worsening high blood pressure has happened in people treated with IMBRUVICA®. Your healthcare provider may start you on blood pressure medicine or change current medicines to treat your blood pressure.
- **Decrease in blood cell counts.** Decreased blood counts (white blood cells, platelets, and red blood cells) are common with IMBRUVICA®, but can also be severe. Your healthcare provider should do monthly blood tests to check your blood counts.
- **Second primary cancers.** New cancers have happened during treatment with IMBRUVICA®, including cancers of the skin or other organs.
- **Tumor lysis syndrome (TLS).** TLS is caused by the fast breakdown of cancer cells. TLS can cause kidney failure and the need for dialysis treatment, abnormal heart rhythm, seizure, and sometimes death. Your healthcare provider may do blood tests to check you for TLS.

The most common side effects of IMBRUVICA® in adults with B-cell malignancies (CLL/SLL and WM) include:

- diarrhea
- tiredness
- muscle and bone pain
- rash
- bruising
- nausea

Diarrhea is a common side effect in people who take IMBRUVICA®. Drink plenty of fluids during treatment with IMBRUVICA® to help reduce your risk of losing too much fluid (dehydration) due to diarrhea. Tell your healthcare provider if you have diarrhea that does not go away.

These are not all the possible side effects of IMBRUVICA®. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of IMBRUVICA®

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use IMBRUVICA® for a condition for which it was not prescribed. Do not give IMBRUVICA® to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about IMBRUVICA® that is written for health professionals.

Important Side Effect Information continued on next page.

Please see the accompanying full Important Product Information at www.imbruvica.com/prescribing-information.

imbruvica® (ibrutinib)
420, 280, 140 mg tablets | 140, 70 mg capsules

USES

What is IMBRUVICA® (ibrutinib)?

IMBRUVICA® (ibrutinib) is a prescription medicine used to treat:

- Adults with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL).
- Adults with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion.

It is not known if IMBRUVICA® is safe and effective in children.

Please see the accompanying full Important Product Information at www.imbruvica.com/prescribing-information.

References:

1. Kipps TJ. *Chronic Lymphocytic Leukemia*. Leukemia & Lymphoma Society: Rye Brook, NY; 2017.

2. National Comprehensive Cancer Network. NCCN Guidelines for Patients®: Chronic lymphocytic leukemia. Accessed October 19, 2020. https://www.nccn.org/patients/guidelines/content/PDF/cll-patient.pdf

3. IMBRUVICA® (ibrutinib) Prescribing Information. Pharmacyclics LLC.

4. Burger JA, Tedeschi A, Barr PM, et al; for the RESONATE-2 Investigators. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. *N Engl J Med*. 2015;373(25):2425-2437.

5. IQVIA APLD data. May-July 2022.

imbruvica®
(ibrutinib)
420, 280, 140 mg tablets | 140, 70 mg capsules

Call IMBRUVICA® By Your Side Today

Topics your Ambassador can help you with

Here are some frequent questions your **IMBRUVICA® By Your Side Ambassador** can help answer:

- How can I best plan for conversations with my doctor?
- How can I build a routine with my treatment?
- What resources do you have to help me track side effects?
- How can I learn about my cost and coverage options?

Questions?

Call your **IMBRUVICA® By Your Side Ambassador** Monday-Friday, 8AM-8PM ET at **1-888-YourSide (1-888-968-7743)** or visit **IMBRUVICAByYourSide.com**.

imbruvica® By Your Side Patient Support

imbruvica® (ibrutinib)
420, 280, 140 mg tablets | 140, 70 mg capsules

Please see Important Side Effect Information on pages 15-18.
Please see the accompanying full Important Product Information at www.imbruvica.com/prescribing-information.

For more information about PCYC's privacy practices or how to opt-out, visit https://www.pharmacyclics.com/privacy-notice.html.

pharmacyclics® An AbbVie Company

Pharmacyclics LLC
1000 Gateway Blvd.
South San Francisco, CA 94080

janssen

Janssen Biotech, Inc.
800 Ridgeview Drive
Horsham, PA 19044

11/23 US-IMB-230320